A trial looking at enzastaurin and temozolomide for gliomas (EORTC 26054)

Cancer type:

Brain (and spinal cord) tumours




Phase 1

This trial looked at different doses of enzastaurin and temozolomide for glioma brain tumours.

Doctors usually treat gliomas with surgery, radiotherapy and sometimes chemotherapy. Doctors may suggest having a chemotherapy drug called temozolomide.

In this trial, the researchers wanted to learn more about having enzastaurin at the same time as temozolomide. They hoped that enzastaurin (LY317615) may be able to stop the cancer developing its own blood supply. This is called anti angiogenesis. Other trials had shown that enzastaurin may help people with gliomas, but doctors wanted to find out if it is safe to have this drug at the same time as temozolomide.

The aims of this trial were to find out

  • The best doses of enzastaurin and temozolomide when you have both drugs at the same time
  • What the side effects are
  • If having temozolomide and enzastaurin together helps people with a glioma

Summary of results

The research team found that the combination of enzastaurin and temozolomide was safe, and they recommended a dose to use for future trials.

This phase 1 trial recruited 28 people with glioma that was either newly diagnosed or had come back after treatment. The research team were able to analyse the results of 26 of them.

The people taking part had 1 of 3 doses of enzastaurin

  • A lower dose, once a day
  • A lower dose, twice a day
  • A higher dose, once a day

The research team found that the people who had the lower dose twice a day had the most side effects. They concluded that the best dose to use was the higher dose, once a day.

It is difficult to draw firm conclusions about how well treatment works in a trial this small, but they found that during the trial

  • 3 people’s cancer stopped growing
  • 15 people’s cancer stayed the same size
  • 8 people’s cancer continued to grow

The trial team concluded that enzastaurin and temozolomide could be a useful combination for people with glioma. They also recommended a dose of enzastaurin to be used in future trials.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Roy Rampling

Supported by

Eli Lilly and Company Limited
European Organisation for Research and Treatment of Cancer (EORTC)
Experimental Cancer Medicine Centre (ECMC)

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 2860

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Rhys was only four years old when he was diagnosed with a brain tumour

A picture of Rhys

"He went through six operations and was placed on a clinical trial so he could try new treatments.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think